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Abstract
Background: Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We
conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the
immunological and virological responses in adults.
Methods: Data were extracted from articles that were selected after screening of PubMed/MEDLINE up to
November 2012 and abstracts of the 1996–2012 international conferences. Observational cohorts, clinical trials and
program reports were eligible as long as they reported data on ART response (clinical, immunological or virological)
among HIV-2 infected patients. The determinants investigated included patients’ demographic characteristics,
CD4 cell count at baseline and ART received.
Results: Seventeen reports (involving 976 HIV-2 only and 454 HIV1&2 dually reactive patients) were included in
the final review, and the analysis presented in this report are related to HIV-2 infected patients only. There was no
randomized controlled trial and only two cohorts had enrolled more than 100 HIV-2 only infected patients. The
median CD4 count at ART initiation was 165 cells/mm3, [IQR; 137–201] and the median age at ART initiation was
44 years (IQR: 42–48 years). Ten studies included 103 patients treated with three nucleoside reverse transcriptase
inhibitors (NRTI). Protease inhibitor (PI) based regimens were reported by 16 studies. Before 2009, the most
frequent PIs used were Nelfinavir and Indinavir, whereas it was Lopinavir/ritonavir thereafter. The immunological
response at month-12 was reported in six studies and the mean CD4 cell count increase was +118 cells/μL
(min-max: 45–200 cells/μL).
Conclusion: Overall, clinical and immuno-virologic outcomes in HIV-2 infected individuals treated with ART are
suboptimal. There is a need of randomized controlled trials to improve the management and outcomes of people
living with HIV-2 infection.
Keywords: HIV-2, Clinical response, Immunological response, Virological response, Antiretroviral treatment
Background
Although human immunodeficiency virus type 1 (HIV-1)
infection is responsible for most of the global AIDS pan-
demic, HIV type 2 (HIV-2) is not infrequent in West
Africa and is an additional and important cause of burden
of disease with a limited spread to other regions of the
world [1-3]. Overall in West Africa, between 10 and 20%
of HIV infections include HIV-2 with a significant propor-
tion of dually infected or reactive HIV-1 + 2 individuals
[4,5]. Interestingly, the prevalence of HIV-2 infections
seems to be declining in West Africa, although the rea-
sons remain unclear [1,6-9]. Compared to HIV-1, HIV-2
infection is characterized by a longer clinical asymptom-
atic latency period [10], a slower T lymphocyte CD4
(CD4) depletion [11,12] and a lower plasma viral load
(VL) [13,14]. Nevertheless, HIV-2 infection can lead to
clinical AIDS [15,16] and death [17-19] and such patients
may clearly benefit from antiretroviral therapy (ART).
The 2013 World Health Organization (WHO) guide-
lines recommended the combined use of either three
nucleoside reverse transcriptase inhibitors (NRTIs) or
two NRTIs plus one protease inhibitor (PI) as the initial
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ART regimen for HIV-2 infection in a public health ap-
proach, [20]. These guidelines were based on observa-
tional studies with limited data. Their application could
lead to the unavailability of effective second-line agents
for HIV-2 infected patients in areas with limited access
to ART, since phenotypic cross-resistance with PIs as well
as NRTIs is a significant issue for HIV-2 [21-25].
No randomized clinical trial has assessed the efficacy
of specific ART regimens in treatment-naïve HIV-2–in-
fected patients [26,27]. However, observational cohort
studies in developed countries [15,28,29] have reported
different and generally poorer treatment responses in
HIV-2 patients compared to HIV-1 patients. Similar re-
sults were reported in a larger cohort collaboration in
West Africa [30]. Additionally, data from few cohort
studies conducted in resource-limited settings, such as
Senegal [23-25], Gambia [18,31-33], Cote-d’Ivoire [34]
are focused generally on treatment outcomes or geno-
typing resistance mutation in HIV-2 infected patients.
Data comparing different ARV regimens among HIV-2
patients are even scarcer. Only one European cohort study
has reported better immunological and virological responses
to ritonavir-boosted PI-containing ART in antiretroviral-naïve
HIV-2–infected patients compared to three NRTIs [15].
Overall, there has been minimal evidence-based recommen-
dation regarding the best use of ART for HIV-2 infection
[20,33,35-37]. We initiated this systematic review on ART
response among HIV-2 and HIV-1/HIV-2 dually infected
patients, to describe the different ART options that
have been used and the different outcomes of these
treatments.
Methods
We conducted this systematic review according to the cri-
teria set forth by the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) group [38].
Eligibility criteria
All studies, without design, place or language restrictions,
were considered if they met the following four selection
criteria: 1) data on clinical response (death or worsening
of WHO stage), 2) data on immunological or virological
response or both, sorted by ART regimen, 3) at least five
patients receiving each drug regimen, 4) an available ab-
stract, an article or an oral poster presentation. We in-
cluded retrospective and prospective studies that reported
responses to ART among HIV-2 and HIV-1/HIV-2 dually
infected patients whatever the first-line regimen received.
We excluded the case series with less than five patients.
We also excluded studies that only reported data on geno-
typic analysis or only the prevalence of HIV-2 infection, or
natural history.
Search strategy and study selection
We developed a sensitive search strategy that combined
terms for HIV-2 and ART (HAART or antiretroviral
therapy or highly active or antiretroviral or therapy or
highly active antiretroviral therapy, drug resistance, viral
drug resistance).
(“hiv-2”[MeSH Terms] OR “hiv-2”[All Fields] OR “hiv
2”[All Fields]) AND (“drug resistance, viral”[MeSH
Terms] OR (“drug”[All Fields] AND “resistance”[All
Fields] AND “viral”[All Fields]) OR “viral drug
resistance”[All Fields] OR (“drug“[All Fields] AND
“resistance“[All Fields] AND “viral“[All Fields]) OR
“drug resistance, viral“[All Fields]) AND
(“1996“[PDAT]: “2012“[PDAT]):
(“hiv-2“[MeSH Terms] OR “hiv-2“[All Fields] OR “hiv
2“[All Fields]) AND (“antiretroviral therapy, highly
active”[MeSH Terms] OR (“antiretroviral”[All Fields]
AND “therapy”[All Fields] AND “highly”[All Fields]
AND “active”[All Fields]) OR “highly active
antiretroviral therapy”[All Fields] OR “haart“[All
Fields]) AND (“1996“[PDAT]: “2012“[PDAT])
Initial searches were developed (DKE) for the follow-
ing databases (from 1996 to November 1st, 2012): MED-
LINE via PubMed, EMBASE, LILACS, Web of Science,
Current Controlled Trials (www.controlled-trials.com),
and the Cochrane Central Register of Controlled Trials.
MEDLINE search was subsequently updated to November
1st, 2012. We also searched the data available on websites
of International AIDS Society (IAS) conferences and of
the Conference on Retroviruses and Opportunistic Infec-
tions (CROI) and International Conference for AIDS in
Africa (ICASA). We particularly searched for abstracts
from conferences held between July 2009 and July 2012 in
order to identify studies that were recently completed but
were possibly not yet published as full text articles. Bibli-
ographies of relevant review articles and other papers were
also screened. One of the authors (DKE) did a preliminary
search, scanning all titles for eligibility according to the
predefined inclusion criteria. The full abstracts of poten-
tially eligible studies were then scanned by additional two
reviewers (PC, JT) who worked independently to select
potentially relevant full-text articles. Once all relevant full-
text articles were reviewed, final agreement on study in-
clusion was determined through consensus (PC, DKE, JT
and SPE).
Data extraction and quality assessment
To decide whether or not the eligible studies met the in-
clusion criteria, each report was assessed by two independ-
ent reviewers (DKE, PC) using a standardized selection
form developed for this purpose. Disagreements between
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observers were resolved by discussion. Data extraction was
also conducted by the same reviewers using a standardized
data extraction form created for this study and with the
collaboration of external experts, when needed (JT, SPE).
The following information was obtained from each
study: first author’s name, journal and year of publica-
tion/presentation, design of the study, patient character-
istic at baseline, location of the study, ART details,
baseline median plasma HIV-2 VL, baseline CD4 count
and length of follow-up. Each cohort was divided into
categories according to ART used: PI-based regimen vs
three NRTIs or other.
Outcome measures
The outcomes of interest were the immunological re-
sponse at 6, 12, 24 and 36 months (or equivalent time in
weeks), the virological response at 12 and 24 months (as
proportions at each time point) and the clinical progres-
sion including morbidity, ART discontinuation and mor-
tality. The immunological and virological responses were
considered when at least two measures of CD4 count or
viral load at different moment were provided (one meas-
ure at baseline and at least one measure during follow up).
Data analysis
A wide variation in definitions, outcomes, and specific
components of ART response evaluated in the studies
was observed. This did not allow us to aggregate statis-
tical analysis of findings beyond a basic descriptive level.
We therefore began by describing each study, identify-
ing the ART regimens initiated. We also described the
different outcomes reported in each study. Where pos-
sible, we used the reported data to compute a 95%
confidence interval (CI) for mortality, immunological
response (increase of CD4 cell count) and virological re-
sponse (proportion of patients with VL below the de-
tectable threshold). We were not able to summarize the
viral resistance mutations into one main result by lack
of standardization. We used STATA® software to esti-
mate the median with the inter-quartile range (IQR) for
the quantitative variables.
Ethics statement
This systematic review was based on the data extraction
of the articles published and was not therefore submitted
to any ethic committee for a clearance.
Results
Study characteristics
Our search identified 915 papers and abstracts after re-
moving duplicates. Of these, 835 were excluded on the
basis of title and 39 others were excluded on the basis of
content of the abstracts. Finally, after a full text screen, 25
reports were excluded because of insufficient information
or target population only made up of HIV-1&2 dually re-
active patients. One additional report from CROI web site
was added. Altogether, 17 reports were included in the
final review according to our eligibility criteria (Figure 1).
There were no randomized trials, 15 cohort studies and
two case series. Although the epicentre of HIV-2 is West
Africa, it contributed only 8 studies, one was conducted in
India, another in the USA, six in Europe and one study
failed to adequately report the location. Ten studies in-
volved HIV-2 infected patients only and the remaining in-
cluded at least two or three sub-groups (HIV-2, HIV-1
and/or HIV-1&2 dually reactive) (Table 1).
Table 1 describes the characteristics of these 17 stud-
ies. Only two cohorts had enrolled more than 100 HIV-2
infected patients: one from Europe that recruited in six
countries and enrolled 170 HIV-2 infected patients [15],
and the other one from West Africa with the participation
of sites in five countries and the enrolment of 270 HIV-2
infected patients [30]. For the remaining 15 studies, the
sample size ranged from 5 to 91 HIV-2 infected patients.
The 17 reports contributed 1 430 patients, but only 976
were infected with HIV-2 only and constitute the core sam-
ple for this report. Their median age was 44 years (IQR:
42–48 years). All the studies selected provided a CD4 cell
count at baseline except one from the Netherlands and the
median CD4 cell count at ART initiation was 165 cells/
mm3 (IQR: 138–203). Only six cohort studies reported a
median CD4 cell count ≥200 cells/mm3 at baseline. The
HIV-2 VL at baseline was reported in 10 studies (59%) and
among them the median HIV-2 VL at ART initiation was
3.7 log10 copies/ml, IQR [2.9 - 4.5].
Table 2 describes the antiretroviral drug combinations
used for the HIV-2 infected patients. Ten studies reported
using three NRTIs for a total of 102 patients. Before 2009,
the most frequently used PIs were Nelfinavir or Indinavir
and Lopinavir/ritonavir-based regimens were used there-
after as heat-stable FDC tablets became widely available in
West Africa.
Study outcomes
In our review, 14 studies (82%) reported immunological
response, eight (47%) reported virological response, eight
studies (47%) reported clinical events, and six (35%) re-
ported data on loss to follow-up.
 Mortality and loss to follow-up
A crude mortality rate was reported in eight cohorts
without stratification by drug regimen (Table 3). The
pooled crude mortality rate was 4.8% (37/771).
Benard et al. in a French cohort study reported two
deaths (6.9%) out of 29 HIV-2 infected patients
followed up in median 26 months and treated with
Lopinavir-ritonavir: one from a bladder cancer and
another one from a lung cancer [28]. In the
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European cohort, no death was reported during the
first 12 months of follow-up among 170 HIV-2
infected patients (126 initiated a PI-based regimen
and 44 started with three NRTIs [15]). Studies from
three developing countries reported mortality.
Peterson in the Gambia reported six deaths among
51 HIV-2 infected patients (11.8%) followed up in
median 20 months. In this latter study, the survival
rate was 96% at 12 months and 80% at 36 months
[18]. Smith in Senegal reported seven deaths among
74 HIV-2 infected patients (9.5%) followed up in
median 13 months [43] and in Burkina Faso, Harries
reported 14 deaths among 91 HIV-2 infected
patients (15.4%) followed up in median 23 months
[17]. Loss to follow-up was reported in six studies
and varied between 0% in India [44] to 7.5% in
Burkina-faso [17].
 AIDS progression
In the French cohort, none of the 18 HIV-2 patients
with CDC stage A at baseline and treated with a
PI-based regimen progressed to AIDS during
follow-up. In the European Cohort, among the 170
HIV-2 infected patients enrolled (44 on three
NRTIs), one patient (2%) receiving a triple NRTI
regimen experienced progression to AIDS
(tuberculosis) five months after treatment initiation.
Among patients treated with PI/r, nine (7%)
progressed to AIDS (cytomegalovirus infections
[2], recurrent bacterial pneumonia [1], candidiasis
[1], toxoplasmosis [1], cryptococcosis [1],
pneumocystosis [1], HIV wasting syndrome [1], and
unknown [1]) within a median delay of two months
(min-max: 0.5–7.5 months) after treatment
initiation [15].
Figure 1 Flow chart of the systematic review of antiretroviral therapy (ART) response in HIV-2 infected patients.
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Table 1 Study characteristics of patients initiating antiretroviral therapy in 17 studies
Study (Author, year) Country Sample size Design Population studied Age* Median
(IQR) years
% Male* CD4 count at
baseline*
Viral Load ARV therapy* regimens
(HIV-1, HIV-2, dual
seropositive)
Median log 10 copies*
Adje-Touré, 2003 [34] Côte D’Ivoire 18 Cohort study HIV-2 (n = 18) 41 [36-47] 78% 82 [52–188] 4.5 [4.1-5.2] 83% PI-based regimen (80%
Nelfinavir)
Van Der Ende, 2003 [29] The
Netherlands
20 Cohort study HIV-2 (n = 20) 50 62% 90 [10–360] NR >5 log10 copies (38%) 80% on PI-based regimen
Mullins 2004 [39] USA 10 Case series HIV-2 (n = 9) 43 [35-44] 78% 134 [93–205] NR 44% on PI-based regimen;
22% on PI-boosted regimen
and 11% on NNRTIs
Matheron, 2006 [40] France 61 Cohort study HIV-2 (n = 61) NR NR 136 [57–244] 36 patients 3.1 [1.7-4.2] 77% PI-based regimen 23%
3NRTIs
Ndour, 2006 [41] Senegal 188 Cohort study HIV-2 (n = 35) 41 [29–61] 46% 204 [12–1029] NR 100% on PI-based regimen
(100% on Indinavir)
HIV-1 (n = 153)
Drylewicz, 2008 [12] France 122 Cohort study HIV-1 (n = 59) NR 44% 267 [163–381] 34%, VL <2.7 58% on PI-based therapy
35% on LPV-r
HIV-2 (n = 63) 2.9 [2.4-3.7]
Ruelle, 2008 [42] Belgium
Luxembourg
22 Cohort study HIV-2 (n = 20) 42 52% 226 [124–359] 4.1 [3.4-4.8] 68% on PI-based regimen
32% on 3 NRTIs-
Benard, 2009 [28] France 29 Cohort study HIV-2 (n = 29) 48 [43–55] 52% 142 [59–259] 3.3 [3.0-3.8] 96% PI-based regimen (100%
on LPV-r) 4% 3 NRTIs
Jallow, 2009 [31] Gambia 20 Cohort study HIV-2 (n = 12) Dual
(n = 8)
41 [31-47] 35% 145 [65–210] 4.9 [4.6-5.2] 100% PI-based regimen
(100% on LPV/r)
Gottlieb, 2009 [23] Senegal 23 Cohort study HIV-2 (n = 23) 49 [31–60] 48% 200 [12–562] 30% VL <1.4 2.0 [<1.4-4.3] 96% on PI-based regimen
(100% on Indinavir)
Harries, 2010 [17] Burkina-Faso 4255 Cohort study HIV-2 (n = 91) HIV-1
(n = 4043) Dual
(n = 121)
44 [37-50] 39% 208 [103–459] Not available 70% on PI-based regimen
(27% LPV-r), 1% on 3NRTIS
29% on NNRTI-based
regimen
Drylewicz, 2010 [30] West Africa 5
countries
9482 (270 HIV-2) Cohort study HIV-2 (n = 270) HIV-1
(n = 9482) Dual
(n = 321)
43 [36-50] 46% 148 [77–232] Not available 71% PI-based regimen (31%
on boosted PI)
Smith 2010 [43] Senegal 74 Cohort study HIV-2 (n = 74) 46 [21–64] 32% 202 [2–1124] 2.5 [1.6 – 4.3] AZT 3TC IDV 62% AZT ATC
LPV/r 12%; 3TC D4T IDV 9%;
3TC D4T LPV/Ir 5%; 3TC TDF
LPV/Ir 3% 2–3 NRTI 2%; 2
NRTI 1 NNRTI 3%
Chiara, 2010 [44] India 443 Cohort study Dual (n = 4) HIV-2
(n = 25) HIV- (n = 414)



















Table 1 Study characteristics of patients initiating antiretroviral therapy in 17 studies (Continued)











Peterson, 2011 [18] Gambia 352 (51 HIV-2) Cohort study HIV-1 (n = 308) HIV-2
(n = 51)
42 [32-48] 37% 140 [50–310] 4.9 [4.2-5.4] 88% PI-based regimen (100%
LVP-r) 5% on NNRTI-based
regimen 6% on 3 NRTIs
Benard, 2011 [15] Europe 6
countries
170 Cohort study HIV-2 (n = 170) 46 [39-52] 51% N = 134 191
[90–275]
N = 110 39% VL <2.7 4.0
[3.4-4.6]
74% PI-based (61% on LPV-r)
26% 3NRTIs
Peterson, 2012 [45] NR 5 Case series HIV-2 (n = 5) 50 [41–55] 20% 181 [96–200] NR 5 patients on raltegravir



















The CD4 response was reported in 14 studies
(Table 4). The median CD4 cell count increased at
month-6 after ART initiation was +72 cells/μL
(min-max: +41-140) cells/μL) based on four studies.
In the French cohort [40], the median CD4 cell
count did not differ between patients treated with a
PI-containing regimen and those with three NRTIs
at month-6 (P = 0.47) after treatment initiation.
Always at month-6, in the group of patients without
PI (n = 10), the median CD4 cell count increased
was +57 (min-max: +37; +100) cells/μL whereas it
was +52 (min-max: +8; +81) cells/μL among the
40 HIV-2 infected patients who had initiated a
PI-containing regimen.
Overall, the median CD4 cell count increase at
month 12 after ART initiation was +118 cells/μL
(min-max: +45-200) cells/μL based on six studies. In
France, at month 12 in the group of patients
without PI (n = 9), the median CD4 cell count
increase was +71 (min-max: +0; +90) cells/μL
whereas it was +58 (min-max +11; +130) cells/μL
among the 29 patients who had initiated a
PI-containing regimen [40].
Only one study reported the immunological
response at month-12 per drug regimen [15]. After
three months of treatment, the estimated CD4 cell
count decreased in patients treated with three
NRTIs and increased in those treated with PI/r (−60
vs 176 cells/mm3/year in median; p = 0.002). These
Table 2 First-line antiretroviral treatment initiated in HIV-2 infected patients in 17 studies
Study Study
period
Dual NRTI 3 NRTIs PI-based regimen Boosted PI
(Author, year) Therapy
LPV NFV IDV SQV
Adje-Touré, 2003 [34] 1998-2000 Yes (n = 6) Yes (n = 1) No Yes (n = 7) Yes (n = 4) No
Van Der Ende,
2003 [29]
1995-2001 Yes (n = 0) Yes (n = 2) No Yes (n = 1) Yes (n = 14) Yes (n = 3) 80% boosted PI
Mullins 2004$ [39] 1994-2003 No Yes (n = 2) No Yes (2 ) Yes (n = 2) Yes [3] Ritonavir boosted PI
(n = 2; 22%)
Matheron, 2006 [40] NR- 2004 No Yes (n = 14) No Yes (n = 17) No No Ritonavir boosted PI
(n = 23)
Ndour, 2006 [41] 1998-2004 No No No No Yes (n = 35) No No
Drylewicz, 2008 [12] 1996-2006 No NR Yes (n = 14) Yes (n = 10) Yes (n = 1) No Ritonavir-boosted PI
(n = 24)
Ruelle 2008 [42] NR-2006 No Yes (n = 6) Yes (n = 4) Yes (n = 3) Yes (n = 5) Yes (n = 1) 4 NRTIs (n = 1)
Ritonavir-boosted
PI (n = 10)
Benard A, 2009 [28] NR No No Yes (n = 29) No No No Ritonavir-boosted
(n = 29; 100%)
Jallow, 2009 [31] 2004-2009 No No Yes (n = 20) No No No Ritonavir-boosted
(n = 20; 100%)
Gottlieb, 2009 [23] 2005-NR No No No No Yes (n = 22) No No
Harries 2010 [17] 2002-2008 No Yes (n = 1) Yes (n = 17) Yes (n = 35) Yes (n = 12) No
Drylewicz 2010 [30] 1997-2007 No Yes (n = 21) NR NR NR NR PI = 193 Ritonavir-
boosted (n = 84; 43%)
Smith 2010 [43] NR No Yes (n = 1) Yes (n = 0) No Yes (n = 53) No Ritonavir-boosted
(n = 15; 22.4%)
Chiara, 2010 [44] 2006-2009 No Yes (n = 10) NR NR Yes (n = 15) NR Ritonavir-boosted
(n = 15; 100%)
Peterson 2011 [18] 2004-2009 NR NR Yes [46] No No No Ritonavir-boosted PI
(n = 45, 100%)
Benard, 2011 [15] 1998-2008 No Yes (n = 44) Yes (n = 76) No Yes (n = 18) Yes (n = 16) Ritonavir-boosted PI
(n = 126)
Peterson, 2012 [45] NR Yes (n = 0) No Yes (n = 1) Yes (n = 2) Yes (n = 1) Yes (n = 0) One patient on
raltegravir as first-line
regimen
NR: not reported, NA: not available $ Only the last treatment received was considered.
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changes resulted in estimated CD4 cell counts at
month 12 being lower in patients treated with three
NRTIs than in patients treated with PI/r (191 vs 327
cells/mm3 in median; p = .001). The difference in
estimated median CD4 cell counts at month 12
between patients treated with three NRTIs and
those treated with a boosted PI-containing regimen
remained statistically significant after adjustment
for geographical origin (p = 0.0009) or for baseline
HIV-2 RNA level (p = 0.05) [15].
 Virological response
The virological response was reported in 11 studies
(Table 5). The threshold of detection of HIV-2 VL
varied from one study to another (min-max: 1.4-2.7
log10) (Table 5). Overall, among HIV-2 infected
patients who initiated ART and had VL data
available, 10% to 39% had an undetectable VL at
baseline. In the Gambia, 81% of patients enrolled
had their VL <400 copies/mL [18]. Ruelle et al. [42]
in Belgium and Luxembourg reported that eight
out of 13 HIV-2 infected patients (62%) had
undetectable VL among patients who initiated a
PI-based regimen. On the other hand, among
patients who initiated a regimen without PI, one out
of six (17%) had an undetectable VL at baseline.
Three studies reported virological response data in
patients who initiated a PI-based regimen or another
regimen. Matheron et al. [40] reported a median
change of VL of −1.0 (IQR −1.0; 00) log10 copies/ml
among patients without PI whereas it was −0.6
(−1.7, 00) log10 copies/ml among patients who
initiated a PI-based regimen. A similar report in the
European cohort indicated a change of −1.8 log10
copies/ml among patients initiating a PI-based
regimen and 0 log10 among patients who initiated
ART with three NRTIs [15]. The proportion of
patients with undetectable VL at 36 months was
81.4% in the Gambian study [18].
Discussion
This systematic review illustrates the heterogeneity of
the reports of treatment outcomes of HIV-2 infected
patients initiating ART, especially in resource-limited
settings. Therefore, the global response on ART among













Adje-Touré, 2003 [34] 11 [7-12] NR NR NR NR NR
Van Der Ende, 2003 [29] 23 [13–58] NR NR NR NR 2/13 (15%)
Mullins 2004 [39] 22 [8 – 35] NR 100% NR NR NR
Matheron, 2006 [40] 21 5/61 (15.8%) NR NR NR 3/61 (4.9%)
Ndour, 2006 [41] 10 [1-21] NR NR NR NR NR* (opportunistic
infections 9/35)
Drylewicz, 2008 [12] NR NR NR NR NR NR
Ruelle 2008 [42] NR NR NR NR NR NR
Benard A, 2009 [28] 26 [10-33] 2/29 (6.9%) NR NR NR NR
Jallow, 2009 [31] NR NR NR NR NR NR
Gottlieb, 2009 [23] 17 [4–55] NR NR NR NR NR
Harries, 2010 [17] 23 [8-34] 14/91 (15.4%) NR NR NR NR
Drylewicz 2010 [30] 11 [6-13] 3/270 (1%) NR NR NR NR
Smith 2010 [43] 13 [0–40] 7/74 (9.5%) NR NR NR 24 HIV-AIDS
related events
Chiara, 2010 [44] 36 0/25 (0.0) NR NR NR NR
Peterson 2011 [18] 20 [10-33] 6/51 (11.8%) 96% 89% 80% NR
(89–100) (76–100) (58–100)
Benard, 2011 [15] 20 [8-36] 0/170 (0%) NR NR NR Yes (n = 10)
During the first
12 months
1/44 (2%) 3 NRTIs
9/126 (7%): PI
regimen
Peterson K, 2012 [45] NR NR NR NR NR NR
*Included only the studies which reported virological responses.
NR: Not Reported, VL: viral load.
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Slope of CD4 count
(first period)





82 [52–188] 154 [68–275] 163 [132–244] NR NR NR NR NR
Van Der Ende, 2003
[29]
90 [10–360] 230 [40–380] 270 [60–410] NR NR NR NR 13 patients (Group II)
Mullins 2004 [39] 134[93–205] NR NR NR NR NR NR Median of CD4 count
at the last visit
327 [202–408]
Matheron, 2006 [40] 136 [57–244] 177 181 221 M6: +53 (+10; +86) NR NR At 12 months
[98–328] [123–290] [133–374] No PI: +40 (+18; +97)
M12: +41 (+9; +92)
M24: +62 (9; 120) PI: (+41 (+8, +86)
P (0.67)
Ndour, 2006 [41] 204 [12–1029] NR NR NR Month-12 NR NR NR
+200 cells/mm3




Slope of % of CD4 count
was reported
Ruelle 2008 [42] 226 [124–359] NR NR NR PI containing regimens:
+89 cells/mm3
[−31; 323]






Benard A, 2009 [28] 142 [59–259] M6: +71 [11–116]
M12: +122 [61–159]
M24 + 132 [110–275]




Jallow, 2009 [31] 145 [65–210] NR NR NR NR NR NR NR
Gottlieb, 2009 [23] 200 [12–562] NR NR NR NR NR NR NR
Harries, 2010 [17] 111 [31–171] NR NR NR NR NR NR Means CD4 count
M6 = 255, M12 = 270
Drylewicz 2010 [30] 178 [77–232] NR PI 278 [248–307]
NNRTIs 268
[175–293]




Smith 2010 [43] 202 [2–1124] NR NR NR +8 [−100; +181]
cells/mm3/year
64% CD4 increase and



















Table 4 Immunological responses* among HIV-2 –infected patients in 17 studies (Continued)







NR NR NR NR NR
Peterson 2011 [18] 140 [50–310] NR NR NR M6: +120 cells M12:
+115 cells M24:
+285 cells M36: +280
NR NR NR





NR NR <3 months PI: +12
cells/μl/months 3NRTI:
+6 cells/μl/months
3-12 months PI: +76
cells/μl/y 3NRTI: −60
cells/μl/y





181 [96–200] NR NR NR NR NR NR NR



















Table 5 Virological responses* among HIV-2 –infected patients in 17 studies





(Author, year) Threshold Baseline Month-12 Month −24
% non detectable N, Median [IQR] n, Median [IQR] n, Median [IQR]
Adje-Touré, 2003
[35]
NR 4.5 (4.1-5.2) 4.1 (3.2-4.9) NR NR NR NR
Van Der Ende,
2003 [28]
<2.7 log10 (10%) NR NR NR NR NR NR At week 23, 13/18
(72%) had
VL <2.7 log10
Mullins 2004 <2.0 cp log10 NR NR NR NR NR NR Median viral load









Ndour, 2006 [41] NR NR NR NR NR NR NR NR
Drylewicz, 2008
[12]
<2.7 2.9 NR NR NR <2 months >2 months


















NR 3.3 3 months (n = 20)
80% had
undectable VLN = 24 (33%) [3.0-3.8]
Jallow, 2009 [32] <2.0 log10 4.9 [4.6-5.2] NR NR NR NR NR NR
Gottlieb, 2009 [29] <1.4 log10 N = 23
(30%)






Harries, 2010 [17] NR NR NR NR NR NR NR NR
Drylewicz 2010
[36]


















Table 5 Virological responses* among HIV-2 –infected patients in 17 studies (Continued)







Chiara, 2010 [48] NR NR NR NR NR NR NR NR
Peterson 2011 [18] NR 4.9 [4.2-5.4] 81% VL <400 89% VL <400 NR NR NR 19% expressed
viral rebound by
36 months
Benard, 2011 [15] <2.7 log10 PI: 4.0 [3.4-4.6]
3NRTIs 4.0 [2.9-4.6]
PI: 2.2 3NRTIs 4.0 NR NR 0-3 months 3-12 months










NR NR NR NR NR NR NR NR
*Included only the studies which reported virological responses.


















HIV-2 infected patients remains difficult to synthesize.
By the end of 2012, 17 publications reported usable
information and only one study reported outcomes
stratified by baseline CD4 cells count [15]. Our study
highlights the need for standardized reporting of ART
outcomes among HIV-2 infected patients akin those liv-
ing with HIV-1.
To date, the use of VL for ART monitoring and initi-
ation in HIV-2 infected patients has been a challenge for
two reasons. First, there is no US or European-approved
plasma VL test for HIV-2 infection, although assays are
becoming increasingly available [47,48], second, many
HIV-2 infected patients eligible for ART have an undetect-
able VL. For example, in the European cohort, 39% of
HIV-2 infected patients had an undetectable VL, though
the median CD4 cell count at baseline was 191 cells/mm3
[IQR: 90–275]. Moreover, based on our recent experience
in West Africa among patients with CD4 counts <500
cells/mm3, 76% and 47% of patients had an undetectable
VL when considering thresholds of 50 copies/ml and 10
copies/ml, respectively [47]. Hence, it is more appropriate
at this stage to use patients’ CD4 cell count and clinical
stage for decision on ART initiation, as it has originally
been the standard for HIV-1. However, there is no consen-
sus on the level of CD4 cells count at which to start treat-
ment for HIV-2. The US [37] and British ART guidelines
[35] do not provide specific recommendations on the level
of CD4 cells count at which ART should be initiated
among asymptomatic HIV-2 infected patients. The 2010
French guidelines were the first ones to recommend ART
initiation when the CD4 cell count was below 500 cells/
mm3 [46]. The WHO recommended the same threshold
for HIV-2 and HIV-1 infected patients (CD4 < 350cells/
mm3) in the 2010 version [49] and now the same
threshold for HIV-2 and HIV-1 (CD4 < 500 cells/mm3)
in the recent 2013 recommendation as there was no evi-
dence showing the benefit to start earlier in HIV-2 in-
fected patients [20].
However in most of the reports reviewed, there seems
to be a poorer CD4 cell count recovery after treatment
initiation in HIV-2 infected patients compared to the
HIV-1 infected ones [12]. This systematic review reveals
that the median CD4 cell count at ART initiation was
165 cells/mm3 (IQR; 137–202), which is very close to the
median CD4 count among HIV-1 infected patients in the
same settings [12,30]. Furthermore, the median age at ART
initiation in this report was 44 years for HIV-2 infected pa-
tients (IQR; 42–46 years) and 37 years for the HIV-1 in-
fected ones (Table 1) [30]. In older HIV-1-infected patient
on ART, a poorer immunological response has previously
been reported compared to younger ones in the same part
of the world [50]. It can thus be assumed that poor im-
munological responses could also be expected among
older HIV-2 infected patients. All the aforementioned
argue in favor of early ART initiation among HIV-2
infected patients.
PI-based regimens (usually LPV/r) remains the first-
line therapy most prescribed among HIV-2 infected pa-
tients in accordance with the different guidelines avail-
able [33,35-37]. Data on three NRTI-based regimens, an
alternative for lower-income countries in the context of
the high prevalence of tuberculosis, are limited. The
lack of large observational or randomized treatment
studies in HIV-2 infected patients makes it difficult to
decide at this stage when and which therapy should be
started [26,27]. Hence, there is an urgent need for ran-
domized controlled trials to define the best sequencing
of ART among HIV-2 infected patients, specifically in
areas with limited access to second-line therapy based
on alternative HIV-2 active PIs (Darunavir/r or Saquina-
vir/r) or integrase inhibitor-based regimens. In addition,
optimizing the NRTI backbone in patients failing first-
line regimens is an area that needs to be explored as
data suggest a low barrier to class-wide NRTI resistance
[51]. There is also no report on the switch of first-line
regimens among HIV-2 infected patients. This could be
explained by a lack of clear definition of treatment fail-
ure among HIV-2 infected patients [20,35-37]. In HIV-2
infected patients with virological failure of first-line or
subsequent regimens, genotypic resistance testing may
be beneficial but interpretation algorithms are not well
validated for most ARVs [52]. With this respect, intro-
duction of new drugs and drug classes in countries with
limited resources should be seriously considered.
This is to our knowledge the first systematic review on
ART responses among HIV-2 infected patients including
data from Europe, India and Africa. This review provides
an overview of the different therapeutic strategies that have
been used for HIV-2 infected patients so far, and their
main outcomes, often documented in resource-limited set-
tings but with limited evidence-based conclusions. None-
theless, our review of available data should help to guide
future studies and preferably clinical trials among HIV-2
infected patients.
We found substantial variations of ART responses re-
ported over time and we were thus unable to identify
any preferred ART regimen for HIV-2 infected patients.
Only one study compared two different treatment regi-
mens (PI-based vs. three NRTIs) [15]. In addition, the sub-
stantial heterogeneity in results observed between studies
made it more difficult to determine the magnitude of the
relative influence of individuals’ characteristics on treat-
ment response. The main limitation of this review is the
use of several patient populations probably overlapping
each other, such as ANRS studies [12,28,53] and the Sene-
galese studies [25,39] and the two international collabora-
tive studies ACHIEV2E in Europe [15] and IeDEA West
Africa [30,54] Moreover, it was also challenging to analyze
Ekouevi et al. BMC Infectious Diseases 2014, 14:461 Page 13 of 16
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data in this review because each study reported the main
outcomes in different manner. For example the CD4
count response was presented as an absolute difference
delta or as a slope of CD4 count at different time points.
It is therefore advisable to harmonize data presentation
for future reports on ART response among HIV-2
infected patients. For example, CD4 slopes should be
systematically reported as performed by the European
and West Africa Collaborations [12,15,30]. For all the
above, we were unable to pool the data extracted with
different outcomes reported at different times and the
overlapped study populations; hence we could not per-
form a meta-analysis.
Conclusion
In summary, our review did not find clear evidence on
the response to different ART regimens used for HIV-2
infection mainly based on CD4 counts. This observation
provides further justification to conduct randomized
controlled trials among HIV-2 infected patients.
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